Advertisement
Research Article

Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells

  • Sofia Zanin,

    Affiliation: Department of Biomedical Sciences and National Research Council Institute of Neurosciences, University of Padova, Padova, Italy

    X
  • Christian Borgo,

    Affiliation: Department of Biomedical Sciences and National Research Council Institute of Neurosciences, University of Padova, Padova, Italy

    X
  • Cristina Girardi,

    Affiliation: Department of Biomedical Sciences and National Research Council Institute of Neurosciences, University of Padova, Padova, Italy

    X
  • Sean E. O'Brien,

    Affiliation: Cylene Pharmaceuticals, San Diego, California, United States of America

    X
  • Yoshihiko Miyata,

    Affiliation: Department of Cell and Developmental Biology, Graduate School of Biostudies, Kyoto University, Kyoto, Japan

    X
  • Lorenzo A. Pinna,

    Affiliations: Department of Biomedical Sciences and National Research Council Institute of Neurosciences, University of Padova, Padova, Italy, Venetian Institute of Molecular Medicine, Padova, Italy

    X
  • Arianna Donella-Deana,

    Affiliation: Department of Biomedical Sciences and National Research Council Institute of Neurosciences, University of Padova, Padova, Italy

    X
  • Maria Ruzzene mail

    maria.ruzzene@unipd.it

    Affiliations: Department of Biomedical Sciences and National Research Council Institute of Neurosciences, University of Padova, Padova, Italy, Venetian Institute of Molecular Medicine, Padova, Italy

    X
  • Published: November 08, 2012
  • DOI: 10.1371/journal.pone.0049193

About the Authors

Sofia Zanin, Christian Borgo, Cristina Girardi, Lorenzo A. Pinna, Arianna Donella-Deana, Maria Ruzzene
Department of Biomedical Sciences and National Research Council Institute of Neurosciences, University of Padova, Padova, Italy
Sean E. O'Brien
Cylene Pharmaceuticals, San Diego, California, United States of America
Yoshihiko Miyata
Department of Cell and Developmental Biology, Graduate School of Biostudies, Kyoto University, Kyoto, Japan
Lorenzo A. Pinna, Maria Ruzzene
Venetian Institute of Molecular Medicine, Padova, Italy

Corresponding Author

Email: maria.ruzzene@unipd.it

Competing Interests

SOB is currently employed by Cylene Pharmaceuticals which holds United States patents for CX-4945 (United States 7,956,064) and CX-5011 (United States 7,910,600). This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. The remaining authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: MR ADD LAP. Performed the experiments: SZ CB CG. Analyzed the data: MR SZ CB CG ADD. Contributed reagents/materials/analysis tools: SOB YM. Wrote the paper: MR.